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Historical Perspective 
FIRST DESCRIPTION AND SEARCH FOR 
AETIOLOGY 
A number of the characteristics of the disease known today 
as sarcoidosis were first described in the 18th and 19th 
centuries. In 1798, erythema nodosum was described by 
R. William, and as early as 1882, the microscopical charac- 
teristics of epitheloid and giant cells were reported by M. 
Tenneson. In 1889, Ernest Besnier, a French dermatologist 
at the Hopital St. Louis in Paris, presented a 34-year-old 
man with lesions on the face and upper limbs ‘of a type 
incompletely known and described’. Initial manifestations 
of the disease had been observed 10 years prior to the 
clinical presentation as redness of the ears, and 3 years 
later, the nose and the synovial sheaths of the fingers had 
also become affected. Besnier characterized the facial 
changes as ‘une variete de lupus Crythemateux B forme 
d’erytheme pernio ou d’asphyxie local’, which he con- 
sidered related to lupus erythematodous, an auto-immune 
disorder characterized by facial skin lesions(l). The term 
‘lupus pernio’ shaped by Besnier is still used today to 
describe facial skin lesions of sarcoidosis patients. 
The first patient with confirmed skin lesions of sarcoi- 
dosis was described by Jonathan Hutchinson in early 
1880. He called the disease ‘Mortimer’s malady’ after his 
first patient. The case was presented at a meeting of the 
Dermatological Society of London where it was suggested 
to obtain biopsies for microscopic examination (Plate 1). 
Hutchinson recorded that he subsequently proposed this to 
the patient, with the result that he did not see her again for 
2 years. At necropsy, in 1900, it was determined that the 
skin lesions of Mortimer’s malady were identical with those 
described previously by C. Boeck as ‘multiple sarcoids’. 
Thus, Hutchinson was, in fact, preceded by Boeck in the 
histological description of sarcoidosis. 
In 1899, Caesar Boeck (Oslo) described the case of a man 
aged 36 years, presenting with scattered spots and patches 
on the skin. The patches were slightly elevated with pal- 
pable well-defined nodules and infiltrations. In addition, he 
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recorded swollen lymph nodes in the cervical, axillary and 
cubital regions. Boeck removed two skin nodules for histo- 
logical examination, one recent, the other more advanced. 
He found ‘through the whole depth of the corium from the 
papillary layer to the limits of the subcutaneous tissue, 
sharply circumscribed foci of a new growth’, whose ‘cells 
were of the type of epitheloid connective-tissue cells . . 
The nuclei were sometimes multiple . . .’ and ‘in a few 
instances, true giants cells of sarcomatous type. Mitosis was 
scarcely anywhere to be detected’. He proposed the term 
‘multiple benign sarcoid of the skin’ to indicate, in a general 
way, the connective-tissue origin of the lesions. Boeck was 
therefore not only the first investigator to describe the skin 
lesion of the disease now generally referred to as sarcoi- 
dosis, but also its histology, and presence of lymph node 
involvement (2). By 1916, he gained an understanding of 
the identity of Besnier’s lupus pernio with sarcoid of the 
skin. It may be assumed that the first sarcoidosis patient 
seen by Boeck had a spontaneous remission of the disease. 
He died at the age of 80 years from a hypernephroma with 
metastases, and at necropsy, no clinical or pathological 
evidence of sarcoidosis was found. 
Sarcoidosis is regarded today as a systemic disorder 
which can affect virtually all organs of the body. This view 
is based on the work of Kuznitzky, Bittorf and Schaumann. 
In 1914, Jiirgen Schaumann, a Swedish dermatologist, 
wrote a prize-winning essay on lupus pernio, in which he 
expressed the view that Besnier’s lupus pernio and Boeck’s 
multiple sarcoids are manifestations of the same disease, 
that this disease might also involve the lymph nodes, the 
mucosa of the nose, the tonsils, the bones and the lungs, 
and that all of these manifestations are characterized by a 
histological pattern which he summarized as a ‘tuberculoid 
granulomatous process’. Schaumann suggested the term 
‘lymphogranulomatosis benigna’ for the disease, since it 
appears to predominantly involve the lymphatic system. In 
this essay published in 1934, he identified radiographic 
changes of the bone due to sarcoidosis and typical 
histological changes in different organs, thus demonstrating 
that an affection of the skin is not mandatory for the 
diagnosis of sarcoidosis (3,4). 
In 1915, Kuznizky and Bittorf (Wrozlaw) reported a case 
of Boeck’s sarcoid with clinically and radiographically 
demonstrable lung changes in the presence of the affection 
of other internal organs. The authors suggested that, in 
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PLATE 1. Mrs Mortimer, the first documented case of 
sarcoidosis. 
this case, the internal organs were involved in a disease 
process similar to that causing Boeck’s sarcoid of the 
skin, and concluded that this constituted a hitherto 
unrecognized disease of the internal organs, particularly the 
lungs (5). 
The name Morbus Besnier-Boeck-Schaumann is still in 
use in the field of dermatology. Although not entirely 
correct, in internal medicine, this disease continues to be 
referred to as sarcoidosis, which is due to the fact that its 
aetiology remains unknown and it has thus not been 
possible to substitute the name with one based on aetiology. 
As early as 1905, Boeck described sarcoidosis as ‘a 
bacillary infectious disease, which is either identical to 
tuberculosis or closely related to it’; however, proof of 
this hypothesis remains elusive and there is an ongoing 
discussion of this question. Using methods of histology 
and molecular biology, the presence of acid-fast rods, 
mycobacterial DNA and mycobacterial rRNA has been 
demonstrated in sarcoidosis (68). However, other 
investigators have not been able to reproduce these findings 
and, based on the assumption that per lo6 host cells of 
established lesions, more than 15 organisms are required 
to play a pathogenetic role, it has been concluded that 
Mycobacterium tuberculosis or other mycobacteria are not 
involved in sarcoidosis (9-l 1). 
Epidemiological data and similarities with other infec- 
tious diseases support the hypothesis that sarcoidosis is 
induced by an infectious agent. Seasonal clusterings of 
sarcoidosis in the months of June and July (12) time and 
space clusters (13,14), an increased incidence in health 
workers (15), and the transmission of sarcoidosis by trans- 
plants (16) have been observed and further support the 
hypothesis of transmissible agents inducing sarcoidosis. For 
example, Borrelia burgdorferi has recently been proposed 
as a possible cause of sarcoidosis (17,18); however, 
data obtained by the authors’ group do not support this 
hypothesis (19). Additionally, a recent report could demon- 
strate the presence of antibodies to Chlamydia pneumoniae 
LPS in 20 of 24 sera from patients with sarcoidosis (20). 
However, at least in Germany, the prevalence of antibodies 
to Chlamydia is high and therefore the precence of 
Chlamydia species in patients with sarcoidosis should be 
evaluated carefully. Nevertheless, the intracellular pathogen 
ChlamJjdia might be an interesting candidate involved in the 
pathogenesis of sarcoidosis. Most interestingly, there are 
case reports of sarcoidosis patients who suffered from a 
relapse of sarcoidosis in a transplanted lung, despite receiv- 
ing immunosuppressive therapy. Vice versa, a patient 
receiving a lung from a donor who had a spontaneous 
remission of sarcoidosis in the past, was observed to 
develop sarcoid-like lesions. These observations suggest the 
aetiological agent to hide within the lung and/or in other 
compartments of the body. Despite efforts made to eluci- 
date the aetiology, the statement made by Longcope and 
Freimann in 1952 is still true: 
‘The aetiology of sarcoidosis is still obscure, the rela- 
tion which it bears to tuberculosis or possibly other 
forms of granulomata remains a matter of contention 
and the conclusive demonstration of its presence rests 
entirely upon the histological structure of the lesions 
which it produces, The most telling contribution that 
could be made to our knowledge of this peculiar 
condition would be the discovery of its aetiology’ (21). 
THE KVEIM-SILTZBACH TEST 
Based on the hypothesis that sarcoidosis might be an 
infectious disease, several investigators have attempted to 
develop skin tests similar to that of Mendel and Mantoux 
for tuberculosis. Williams and Nickerson reported in 1935 
that within 24 h, the intradermal inoculation of a prep- 
aration of sarcoid tissue into four patients with suspected 
sarcoidosis and four normal control subjects yielded 
firm red papules in the sarcoid group (22). A. Kveim, a 
dermatologist from the Christiania Hospital in Oslo, sub- 
sequently made the important observation that these 
papules consist of sarcoid tissue. In 14 weeks following the 
intracutaneous inoculation of a heat-killed lymph node 
suspension, he obtained histological evidence of sarcoid 
tissue from the injection site in 12 of 13 patients 
with sarcoidosis. There was no reaction in patients with 
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cutaneous tuberculosis (lupus vulgaris), leading him to 
conclude that the sarcoid papules were specific lesions due 
to an unknown agent (23). M. Chase proposed a standard- 
ized procedure for the preparation of the test reagent ~ still 
in use today - (24) L. Siltzbach performed comprehensive 
studies establishing the practicability of the test as a diag- 
nostic tool (25) and the Kveim-Siltzbach test is till applied 
in a number of countries for the diagnosis of sarcoidosis. 
Up to now, the nature of the Kveim reagent is obscure. 
Denaturing experiments have revealed that the active, 
granuloma-inducing principle should consist of a protein 
and depends on its three dimensional structure (26). T-cells 
from sarcoid patients do not proliferate after stimulation 
with Kveim reagent (27) and despite of many attempts, it 
has not been possible to develop an in vitro test for clinical 
routine purposes (28). Employing different immuno- 
electrophoretic methods, Reutgen et al. could demonstrate 
3-l 1 precipitation lines in the Kveim reagent (29). Immuno- 
histochemical stainings with antisera or monoclonal anti- 
bodies to Kveim reagent showed reactivity to epitheloid 
cells in sarcoid granulomas and, to a lesser extent, in 
tuberculoid granulomas (29,30). Additional studies 
revealed that the anti-Kveim-reagent monoclonal antibody 
recognizes both epithelial cells and giant cells from granu- 
lomas from patients with summer-type hypersensitivity 
pneumonitis, Crohn’s disease, foreign body granuloma and 
Wegener’s granulomatosis. These data show that at least 
one fraction of this preparation consists of proteins related 
to granuloma development in general, and are not specific 
for sarcoidosis. 
BRONCHOALVEOLAR LAVAGE 
The technique of bronchoalveolar lavage was introduced 
in 1920 (31). The first article describing pulmonary 
alveolar lavage as a method for harvesting large numbers 
of macrophages from the rabbit lung was not published 
until 1961 by Myrvik et al. (32). Finley et al. have demon- 
strated that bronchoalveolar lavage can be performed 
safely in humans using a wedged catheter (33). With the 
introduction of the fibreoptic bronchoscope into clinical 
medicine by S. Ikeda (34) bronchoalveolar lavage has 
become widely used for clinical investigations (3536). The 
observation of characteristic changes in the cytology of 
bronchoalveolar lavage in interstitial lung diseases, first 
reported by G. Hunninghake in 1971, gave rise to a large 
number of detailed investigations of pulmonary im- 
munology in health and disease (37). The findings 
obtained by various researchers over the last 15 years form 
the basis of a concept of the immunopathogenesis of 
sarcoidosis discussed below. 
Immunopathogenesis 
ULTRASTRUCTURAL CHANGES 
In addition to granulomas, the morphologic appearance of 
sarcoid of the lung has many of the features typical of mild 
interstitial lung diseases. Early in the disease, unspecific 
ultrastructural lesions of the air-blood barrier can be 
observed, frequently even in areas of the lung which appear 
normal using light microscopy. The alveolar walls are 
expanded. The type I epithelial cells of the alveoli are 
injured, denuding the basal membrane of a number of 
alveoli (Plate 2). These defects are covered by cuboidal cells, 
primarily pneumocytes type II. In other areas, the endothe- 
lial cells are damaged, and capillaries are replaced by 
connective tissue. In rare cases, a fibroblast proliferation in 
the alveolar and/or bronchial walls can be observed; it is 
these cases in which various amounts of dense fibrosis are 
observed, replacing the normal parenchymal structures 
(38), thus hindering the gas exchange. 
Similar lesions can be observed in various clinical or 
experimental conditions including asbestosis (39), idio- 
pathic pulmonary fibrosis (39,40), pulmonary histiocytosis 
X (41), systemic sclerosis with lung involvement (42), early 
stages of adult respiratory distress syndrome (ARDS) (43) 
X-ray irradiation, paraquat, bleomycin or 3-methylindole 
toxicity (44,45), and exposure to nitrogen or oxygen (44). 
The occurrence of similar reactions in such different con- 
ditions supports the concept of a common pattern of 
pulmonary response to diverse injuries. 
A sequela of the early damage to the basal membrane in 
interstitial lung diseases is a change in the composition of 
the alveolar lining fluid. Albumin and glucose are found at 
high concentrations in the alveolar lining fluid of patients 
with sarcoidosis (46), which may be due to leakage in the 
basal membrane or due to a defect of the epithelial cells 
resulting in a decreased transmembrane transportation rate 
from the alveolar lumen back to the interstitium. These 
changes correlate with various parameters of inflammation, 
e.g. cellularity of bronchoalveolar lavage (46). In addition, 
dramatic changes in the composition of the surfactant are 
observed in interstitial lung diseases, indicating an alter- 
ation in type II epithelial cells which produce the surfactant 
proteins and phospholipids (47,48). These proteins are now 
recognized to exhibit immunomodulatory functions, either 
anti- or pro-inflammatory in nature (47,49,50). The patho- 
physiological role of the interaction of epithelial lining fluid 
components and cells of the lower respiratory tract are 
unknown, and represent a new and exciting field of 
research. 
T-CELLS 
Sarcoidosis is associated with an increase in the number of 
alveolar T-cells, and a shift to an increase in CD4’ cells 
within these cells can be observed. In normal bronchoalveo- 
lar lavage, up to 20% T-cells with a CD4/CD8 ratio ranging 
from 1.0 to 2.0 may be found. Apart from a small number 
of neutrophils (~5%) the remaining cells are alveolar 
macrophages. In some cases of sarcoidosis, more than 50% 
T-cells with a CD4/CD8 ratio >lO can be observed 
exhibiting markers of activation, such as increased 
HLA-DR, VLA-1 and IL-2 receptor expression and 
capping of the T-cell-antigen receptor (37,51-55). 
These T-cells have been found to release in vitro 
interleukin-2 (IL-2) without any stimulation in tissue cul- 
ture. This finding represents the first demonstration of the 
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PLATE 2. Ultrastructural pulmonary lesions in sarcoidosis. (a) Swelling of a type I epithelial cell (Ep) partially detached 
from its basement membrane (arrows); AS, alveolar space; En, endothelial cell; rbc, red blood cell; bar= 1 pm. 
(b) Necrosis of epithelial cells with accumulation of cell debris in the alveolar space in association with fibrinous deposits 
(F). The epithelial basement membrane is partially denuded (arrows); Cl, capillary lumen; bar= 1 pm. (c) Complete 
destruction of type I epithelial cells leading to basement membrane denuded over a great distance (arrowheads). A 
myofibroblast (MF) is present inside the alveolar wall, extending elongated cytoplasmic processes that come in contact 
with the epithelial basement membranes (arrows); ie, interstitial oedema; bar= 1 pm. Figure reproduced from (38). 
involvement of IL-2 in the immunopathophysiology of a 
disease (56,57). Despite the systemic nature of the disease, 
only the alveolar T-cells (not those of the peripheral blood) 
secreted IL-2. Interestingly, the regulation of the transcript 
of the IL-2 gene appeared to be normal, indicating a 
stimulation of the cells in a physiological fashion (5458). 
This view is supported by the finding of duBois et al. who 
demonstrated a capping of the T-cell-antigen receptor of 
alveolar T-cells in sarcoidosis, suggesting a recent 
activation of the cells via this complex (55). These two 
phenomena can be observed in cells of the bronchoalveolar 
lavage, indicating that the eliciting agent resides in the lung, 
or that activated cells are attracted to the lung (59). 
The enumeration of interleukin-2 receptor-(IL-2R)- 
positive T-cells was considered to be an approach to 
estimate the number of activated alveolar T-cells. Only a 
moderate increase in IL-2R+ T-cells was observed 
(54,58,60-62) suggesting the presence of a small number of 
activated cells in the alveolar space, or a dysregulation in 
the expression of the IL-2R. Results obtained by an in vitro 
study with sarcoid T-cells excluded the latter possibility 
(54). Other immunological disorders, e.g. rheumatoid 
arthritis and multiple sclerosis, also exhibit small increases 
in IL-2R’ T-cells at the synovial surface and in the multiple 
sclerosis lesions, respectively, thus supporting the above- 
mentioned finding (63,64). However, the milieu of the 
lower respiratory tract generated by type II epithelial cells 
modulates the reactivity of the T-cells. In the presence of 
type II epithelial cells, activated T-cells are arrested and do 
not progress in the cell cycle. This blockade is reversed, for 
example, after migration of the T-cells to the lymph node 
(65). The described scenario may also apply to sarcoidosis 
where a lymphocyte proliferation can be observed in 
sarcoid lymph nodes (66). 
A dysregulation of the cellular immune response, 
however, can not be excluded. A recent study has demon- 
strated an inadequate downregulation of activated sarcoid 
T-cells at the level of G-proteins and hydrolysis of CAMP, 
suggesting a T-cell defect causative of the T-cell activation 
observed in sarcoidosis (67). 
Studies with the Kveim reagent revealed that its active 
principle resides within the membrane fragments of alveolar 
macrophages, thus corroborating the hypothesis that a 
sarcoid-specific antigen is presented by these cells (68). 
However, an antigen has not yet been identified. Therefore, 
a number of researchers have analysed the usage of the 
T-cell-antigen-receptor V-region and C-region repertoire in 
sarcoidosis. 
The underlying assumption of this approach is that T-cell 
clones are activated and expanded by the postulated 
‘sarcoid antigen’, resulting in an increased usage of certain 
V-region families of the T-cell-antigen receptor which can 
be evaluated by staining or by identifying the V-region 
mRNA in these T-lymphocytes. 
Moller et al. were the first to demonstrate a bias towards 
an increased usage of the V$ region of the T-cell-antigen 
receptor in sarcoidosis peripheral blood and broncho- 
alveolar lavage T-lymphocytes, suggesting that T-cells 
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accumulate secondary to external selective pressure, rather 
than in a random polyclonal fashion or by clonal expansion 
of one or a few T-cell clones (69). This observation has 
been extended, showing restricted usage of T-cell antigen 
receptor V, (70), VP (71) and Co-chains (72) in broncho- 
alveolar lavage and lung parenchyma (73). However, a clear 
distinction between poly- or oligoclonal T-cell proliferation 
in sarcoidosis could not be made. Other technical 
approaches have demonstrated an increased clonality in 
bronchoalveolar lavage cells without detecting preferred 
V-region families, leading to the assumption that the major 
source of T-cells contributing about 10% of the T-cells is a 
polyclonal unspecific accumulation accompanied by a 
clonal expansion (74,75). In these studies, sarcoidosis was 
not observed to select certain V, families of the T-cell- 
antigen receptor in the detected clones, thus supporting the 
hypothesis of an unspecific stimulus. However, Klein et al. 
demonstrated an increased percentage of Vp2, V,,,3, VP6 and 
V,S families in intradermal lesions of Kveim skin tests 
compared to peripheral blood, and that this increase is 
oligoclonal (76). These findings are consistent with an 
antigen-driven T-cell activation. Limited clonality of T-cells 
could also be demonstrated in lung T-cells (77). The associ- 
ation of this oligoclonality to the course of the disease is 
demonstrated by the fact that oligoclonality decreases after 
clinical improvement of the disease, either by spontaneous 
remission or after corticoid therapy. Additionally, in some 
cases, an amino acid motif in the ViJfl-region of the 
TCR could be identified which has not been described 
before, and might therefore be typical for sarcoidosis (71). 
These data suggest that, at least in part, the immune 
response is elicited by a ‘sarcoid antigen’. In view of the 
absence of a clonal expansion of one distinct V, family, the 
hypothesis of a superantigen as a possible causative agent 
of sarcoidosis can be excluded. 
In the last few years, two functional distinct subsets of 
CD4+ T-cells have been described by their capacity to 
release a definite panel of cytokines, first in the mouse 
(78,79) and later in the human system (80). The Thl cells 
release IL-2, IFNy and lymphotoxin and are related to cell- 
mediated immunity, and Th2 cells release IL-4, IL-5, IL-10 
and IL-13 and are related to B-cell help. Both lineages 
derive from naive ThO cells which are able to release the 
whole panel of cytokines and differentiate in either Thl or 
Th2 cells after antigen stimulation, depending on antigen 
concentration, the affinity of the antigen to the MHC class 
II molecules, and the nature of the antigen. In sarcoidosis, 
spontaneous release of Thl cytokines IFNy and IL-2 by 
BAL T-cells can be demonstrated (56,81), but not of Th2 
cytokines (82,83). Indeed, Baumer et al. demonstrated that 
T-cell clones derived from peripheral blood (PB), BAL cells 
and transbronchial biopsies (TBB) of sarcoid patients 
disclose the entire spectrum of cytokine patterns. Th2-like 
cells could be demonstrated in all three body compartments 
including BAL (84). From this, one can assume that 
although Th2 cells are present, they are not activated or 
even suppressed, which may contribute to the immuno- 
pathogenesis by maintaining a cytokine imbalance in the 
lung. The importance of the cytokine balance for the 
development of a disease might be demonstrated by an 
asthma patient with improving asthma (a Th2 disease) 
during an attack of active sarcoidosis (a Thl disease) (85). 
In addition to the bias described in the usage of the a/P 
T-cell-antigen receptor, a bias in the use of the y/6 T-cell- 
antigen receptor has been observed. In some sarcoidosis 
patients, elevated numbers of $6 T-cell-antigen-receptor- 
positive blood and lavage lymphocytes have been reported 
(86-88); a bias for the use of some V,-chain genes was 
identified and these cells exhibited signs of recent activation 
(89,90). The observation of increased levels of circulating 
y/S T-cells has renewed interest in the potential role of 
mycobacteria in the aetiology of sarcoidosis. Tazi et al. 
have demonstrated that the majority of T-cells in lymph 
node granulomas and in Kveim granulomas of sarcoid 
patients are u//I T-cells (91). 
The majority of the findings with regard to sarcoid T-cell 
response are characteristic of a T-cell-mediated response to 
antigen and are highly suggestive of the presence of a 
persistent, poorly degradable antigen or antigens. This 
concept is further supported by studies of auto-immune and 
chronic inflammatory diseases demonstrating a compart- 
mentalized accumulation of T-cells with restricted VB-chain 
gene usage (92-94). 
ALVEOLAR MACROPHAGES 
Due to a considerable increase in lavage cellularity, the 
absolute number of alveolar macrophages expands in 
sarcoidosis while the relative number decreases. The 
percentage of alveolar macrophages with monocytic 
appearance is elevated in sarcoidosis and idiopathic 
pulmonary fibrosis, suggesting a recent immigration of 
monocytic precursors of alveolar macrophages from the 
blood (95,96). A number of cytokines chemotactic for 
monocytes are produced by alveolar cells in the course of 
inflammatory reactions of sarcoidosis and other interstitial 
lung diseases (97-100) supporting the notion of monocyte 
immigration. However, those markers characteristic for a 
monocytic immunophenotype can be acquired by alveolar 
macrophages in the course of activation (101). Thus, the 
question of monocyte immigration is not yet settled. 
The activated state of these cells has been demonstrated 
on the basis of their spontaneous in vitro production of 
interleukin-1 and the presence of interleukin-l/I mRNA 
(102-107). In addition, interleukin-1 inhibitors and 
interleukin- 1 receptor antagonist were identified in 
bronchoalveolar lavage fluid and cell culture supernatants 
(108,109). 
Since the publication of the above results, a number of 
monokines, i.e. tumour necrosis factor a (TNFa), 
interleukin-6, macrophage inflammatory protein-l and 
monocyte chemotactic protein-l, have been identified to be 
released by alveolar macrophages in the course of sarcoid- 
osis (98,99,103-105,110,111). As described for the T-cell 
activation, the activation of the cells of the monocyte/ 
macrophage lineage is also compartmentalized; i.e. alveolar 
macrophages release these mediators spontaneously, 
whereas the corresponding cells of the peripheral blood are 
quiescent. Kinetic studies on the transcription of the TNFa 
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gene revealed that maximal mRNA transcription is reached 
within 2 h after stimulation. Cytoplasmic TNFa WaS 
detected as early as 1 h after stimulation, culminating 
during the next 2 h to be followed by a decline (112). 
Similar experiments with sarcoid alveolar macrophages 
revealed the transcription of the TNFa gene at the time 
of bronchoalveolar lavage and its downregulation during 
the next 24 h in cell culture (104). Thus, the heightened 
spontaneous TNFa release seen in active sarcoidosis is 
the consequence of an in vivo activation step just prior to 
the removal of the cells from the lung, indicating that the 
eliciting agent resides in the lower respiratory tract. 
TNFu, in particular, is released at high concentrations; 
however, a corresponding cachectin effect is absent in most 
patients, giving rise to the hypothesis that TNFa-binding 
or -neutralizing proteins or counter-acting cytokines are 
simultaneously released (113). Various in vitro anti- 
inflammatory effects of IL-6 can be observed (114), suggest- 
ing that IL-6 may be a factor dampening the alveolitis of 
sarcoidosis. However, IL-6 is co-expressed in sarcoid 
alveolar macrophages, with TNFa and other monokines 
devalidating this hypothesis (105,110). Furthermore, 
soluble TNF receptors (sTNF-R) may as well be capable of 
counteracting TNFu effects (115,116). Preliminary results 
obtained by the authors’ group demonstrate the presence of 
increased sTNF-R serum levels correlating with alveolar 
macrophage TNFa release, and might therefore play a role 
in dampening the cachectin effects of TNFn as observed in 
a number of diseases (117). 
Subsequent cytokine studies were extended to include the 
interstitium and the lymph nodes showing a simultaneous 
activation of alveolar macrophages, interstitial macro- 
phages and macrophages in the granulomas (118-120). In 
general, interstitial macrophages differ from alveolar 
macrophages in the relative expression of immunological 
functions. The latter are poor accessory cells and IL-l 
producers, but appear to be better equipped to clear 
infectious agents from the lower respiratory tract, whereas 
interstitial macrophages have higher accessory and 
immunoregulatory capabilities (121-126). In marked con- 
trast, the accessory capabilities of sarcoid alveolar macro- 
phages have been found to be increased as measured in 
mixed lymphocyte reactions and antigen presentation 
(125,127). The interpretation of these experiments has. 
however, been complicated by possible stimulations via 
minor histocompatibility antigens or by intrinsic activities 
of autologous sarcoid T-cells present in the test. In a 
different cell culture system using a method insensitive to 
histoincompatibilities sarcoid alveolar macrophages were 
shown to express increased accessory functions mediated 
by adhesion molecules, e.g. CD80 (128). This increased 
accessory function could only be demonstrated in patients 
with active sarcoidosis (Group 2: with indication for 
therapy; Group 3: spontaneous remission after 6 months), 
but not in patients with inactive sarcoidosis (Group 1) 
or controls (Fig. 1). Additionally, alveolar macrophages 
from patients with other granulomatous (tuberculosis, 
hypersensitivity pneumonitis and Wegener’s disease) and 
non-granulomatous lung diseases (undefined alveolitis and 
chronic obstructive pulmonary disease) also disclosed 
14, 
t 
0  
12 1 O 
10 
G 
4 F 0 
' -2 8 0 
.3 
I 0 
0 
2 5: 0 z 6 0 
: 
0 
4 
0 
0 0 
- 0 b 00 i hk 
2 
0 
0 
0 
0 
co 
0 0 
LO 
--ET 
0 @ 0 
ego 0 00 0 
0 
0 
Control Group 2 TB WD UA 
Group 1 Group 3 HP COPD 
n: 20 12 19 10 12 12 2 8 6 
FIG. 1. Accessory indices of alveolar macrophages from 
patients with different granulomatous and non- 
granulomatous lung diseases. Horizontal lines indicate 
the means, figures below the groups the number of 
individuals per group. Controls and Sarcoid Group I 
disclose no differences in AI, increase of AI of patients 
with WD was not significant due to the low number of 
patients. The AI of all other patients was significantly 
increased (P<O.O5). 
increased accessory function of alveolar macrophages, 
suggesting that this increase is an unspecific stimulation 
marker of these cells. One mechanism of the induction of 
CD80 and CD86 is the interaction of MHC class II 
molecules with the T-cell receptor (129,130). Additionally, 
increased accessory function can be induced by T-cell- 
derived cytokines like IL-2 (131) or IFN, (unpubl. obs.). 
This again indicates that T-cell activation, possibly by a 
nominal antigen, is involved in the pathogenesis of sar- 
coidosis. It is hypothesized that co-stimulation by CD80 
and CD86 influences the differentiation of Thl/Th2 cells, 
as CD80 co-stimulation leads more to an activation of 
Thl cells whereas CDS6 co-stimulation induces merely Th2 
cells (132-l 35). Therefore, increased accessory function 
of alveolar macrophages influences the composition of 
alveolar T-cells and the cytokine pattern in the lower 
respiratory tract. 
A pathomechanism damaging the epithelia of the lower 
respiratory tract during inflammation is the release of 
radical oxygen intermediates by alveolar macrophages and 
neutrophils. Sarcoid alveolar macrophages and peripheral 
blood monocytes have been shown to release these com- 
pounds in parallel to some parameters of inflammation, 
e.g. expression of adhesion molecules (136-142). In idio- 
pathic pulmonary fibrosis, alveolar immune cells release 
tremendous amounts of radical oxygen intermediates 
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believed to induce fibrosis by permanent destruction 
of epithelia and by interrupting repair mechanisms 
(95142-146). Comparing the oxygen radical burden of the 
lower respiratory tract reveals that in active sarcoidosis, 
only 30% of the radicals found in idiopathic pulmonary 
fibrosis are released (140,142). The low incidence of fibrosis 
in sarcoidosis indicates that the endogenous scavenger 
systems clear the radical burden, and that sarcoid patients 
will not benefit from therapeutical approaches applying 
pharmaceutical radical scavengers as currently tested for 
idiopathic pulmonary fibrosis (1477149). 
EPITHELIAL CELLS 
Epithelial cells of the lower respiratory tract, especially type 
II pneumocytes, are integrated in the pulmonary immune 
response as demonstrated by their constitutive expression 
of HLA-DR (150) and their expression of adhesion 
molecules such as CD54, CD51 and CD49d (151,152). 
Furthermore, TNFa and IL-l, cytokines present in the 
lower respiratory tract in the course of sarcoidosis, are 
capable of inducing the release of monocyte chemo- 
attractant protein-l and interleukin-8 by pneumocytes II. 
Additionally, type II pneumocytes express co-stimulatory 
molecules like CD58, CD80 and CD86, and are able to 
co-stimulate T-cells (153). In sarcoidosis, the activation of 
these cells is indicated by their production of transforming 
growth factor-/3 (154) their release of KL-6, a mucin-like 
glycoprotein (155), and their upregulation of HLA-DR 
expression (156). 
Although the involvement of pneumocytes II in the 
immunopathology of interstitial lung diseases has been 
demonstrated, their role in sarcoidosis remains to be eluci- 
dated. A number of methodological problems impede their 
investigation. The maintenance of pneumocytes II in tissue 
culture is difficult (157) and they can only be obtained from 
patients with interstitial lung diseases when a diagnostic 
open lung biopsy, currently a rare diagnostic procedure, is 
indicated. The available methods to isolate pneumocytes II 
require a large cell input to obtain sufficient numbers 
of pneumocytes II for cell biological experiments. For 
future research, the preparation techniques need to be 
miniaturized to work with thoracoscopically obtained lung 
biopsies or even with transbronchial biopsies. 
CYTOKINE NETWORK IN SARCOIDOSIS 
The hypotheses outlined above required a cell-cell 
communication either by direct contact or by cytokines. In 
pulmonary fibrosis, the existence of a complex cytokine 
network has been delineated. Competence and progression 
factors for fibroblast growth are secreted by inflammatory 
cells in the induction phase of fibrosis (158160). In the 
subsequent phase of repair, proteins inducing the apoptosis 
of fibroblasts can be found (161). In this complex network, 
the effect of an individual cytokine varies with the state of 
activation of the target cell, the presence of other cytokines 
in the local micro environment, and the ability of the target 
cells to produce arachidonic acid metabolites. 
As mentioned above, a predominance of Thl cells was 
demonstrated in sarcoidosis. One key cytokine for the 
induction of Thl cells is IL-12, a product of activated 
macrophages and a strong inducer of Thl responses. The 
bioactive cytokine (~70) consists of two covalently linked 
subunits (~35 and ~40) which are products of two separate 
genes. The subunits are separately regulated, with ~35 being 
considered as constitutively expressed by many cell types 
and p40 being tightly regulated (162). The presence of Thl 
cells in sarcoid lungs suggests the release of bioactive IL-12 
in this compartment. Indeed, Moller et al. found a higher 
expression of IL-12~40 mRNA and a higher release of 
the bioactive protein in sarcoid BAL cells compared 
with controls (163). This increased level of IL-12 upregu- 
lates the development of Thl cells and amplificates the 
release of Thl cytokines, especially IFNy. This cytokine 
cascade further stimulates alveolar macrophages, and 
contributes to the granulomatous inflammation in the 
sarcoid lung. 
Compared to activating cytokines, deactivating cytokines 
are less well characterized. At present, the most extensively 
investigated deactivating cytokines are IL-10 and trans- 
forming growth factor-p (TGFP). TGFP belongs to the 
superfamily of ubiquitous regulatory proteins which are 
necessary for cell growth, cell differentiation and regulation 
of extracellular matrix production. Growing evidence 
also supports a role of TGFP as an immunomodulator, 
exhibiting pro-inflammatory and anti-inflammatory 
activities (164) and stimulating the development of Thl cells 
(165-167). IL-10 is another potent inhibitor of monocyte/ 
macrophage and T-cell activation. It inhibits the cytokine 
production as well as proliferation of human monocytes 
and T-cells (168). 
IL-10 has not been identified in cell culture supernatants 
of patients with sarcoidosis (82,163,169). TGFD, however, 
was found in supernatants of patients with active disease 
and a spontaneous remission within 6 months after the 
investigation, whereas patients requiring therapy or suffer- 
ing from chronic disease had TGFP-negative lavage cells 
(Fig. 2). Furthermore, a strong and significant negative 
correlation was found between IL-2 and TGFP production 
by bronchoalveolar lavage cells (169). This suggests an 
inhibiting role of TGFP on the IL-2 production of T-cells. 
In context with the literature, the authors conclude from 
this data that the release of TGFB by BAL cells is indicative 
of a mechanism which results in the cessation of inflamma- 
tory processes. Subsequent studies revealed that blocking of 
type II pneumocyte-released TGF/3 with monoclonal anti- 
bodies increases the accessory function of these cells (Zissel, 
unpubl. obs.). Whether TGFD is the key cytokine in 
downregulating the alveolitis or whether it acts in concert 
with other, still unknown mediators, requires further 
investigations. 
In this regard, it is of interest that the activation of T-cells 
via CD28 is resistant to the downregulation by TGFP (170). 
In some patients, an increased expression of CD80, the 
ligand of CD28, on alveolar macrophages has been demon- 
strated, indicating an activation of alveolar T-cells via this 
pathway (128). Thus, the course of the disease might be 
determined by the mode of T-cell activation. 
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FIG. 2. Release of TGFB by the four groups of patients. 
TGFB was measured in supernatants of cultured BAL 
cells (IO6 cells ml ~ ’ 24 h) by a bioassay. Mean TGFP 
release is significantly elevated in Group II (spontaneous 
remission) and in Group IV (patients under therapy) 
indicated by bold lines. In Group I (requiring therapy) 
and Group II (persisting disease), TGFj’ is below the 
upper limit of the normal range (1150 pg ml ~ ‘, marked 
by dashed line). 
Conclusion 
Studies of bronchoalveolar lavage cells have advanced our 
understanding of the immunopathogenesis of sarcoidosis. 
Activated macrophages and T-cells have been identified 
in different compartments of the sarcoid lung, and the 
characteristics of the activation suggest that the cells have 
become activated in the course of a normal immune 
response. The immune cells communicate via a cytokine 
network, and measuring cytokine levels yields subgroups of 
sarcoidosis patients which will have different courses of the 
disease. The causative agent eliciting sarcoidosis is not yet 
identified; however, studies aimed at the identification of 
the elusive agent can now be designed on the basis of the 
current concepts of immunopathogenesis. 
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